上海谊众: 上海谊众药业股份有限公司2025年半年度募集资金存放与实际使用情况的专项报告

Core Points - Shanghai Yizhong Pharmaceutical Co., Ltd. reported on the status of its fundraising and actual usage for the first half of 2025, detailing the total amount raised and how it has been allocated [1][2][4] - The company raised a total of RMB 936.03 million, with a net amount of RMB 936.03 million after deducting issuance costs [1][2] - As of June 30, 2025, the remaining balance of the raised funds was RMB 424.52 million [1][2] Fundraising Overview - The company issued 26.45 million shares at a price of RMB 38.1 per share, resulting in total fundraising of RMB 1,007.75 million [1] - After deducting issuance costs of RMB 71.71 million, the net proceeds amounted to RMB 936.03 million [1] - The funds were deposited in designated accounts and managed according to regulatory requirements [1][2] Fund Management - The company established a fundraising management system to ensure the funds are used in a standardized, safe, efficient, and transparent manner [1][2] - Multiple bank accounts were opened for fund management, including accounts at Agricultural Bank of China, Bank of Communications, and China Merchants Bank [1][2] - The company has approved the temporary use of idle funds for cash management, with limits set for various periods [2][5] Actual Fund Usage - As of June 30, 2025, the company had invested RMB 580.45 million into projects, with RMB 70.77 million invested in the current period [1][4] - The company used RMB 142,358.49 for replacing self-raised funds that were used for issuance costs [1][5] - There were no instances of using excess funds for permanent working capital or repaying bank loans [2][5] Project Progress and Adjustments - The company reported delays in project timelines due to regulatory approvals and external environmental changes [4][6] - Adjustments were made to the investment amounts among different project entities to improve efficiency and ensure timely project completion [6] - The company is actively working on expanding its production capacity for the injectable paclitaxel polymer micelles [6]